US federal health agencies will call for an immediate pause in use of Johnson & Johnson's single-dose COVID-19 vaccine after six US recipients developed a rare disorder involving blood clots, the New York Times reports.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
All the six recipients were women between the ages of 18 and 48. One woman died and a second woman in Nebraska has been hospitalised in critical condition, the NYT reported, citing officials briefed on the decision.
The company's shares were down 3 per cent before the opening bell.
The Food and Drug Administration, Johnson & Johnson and the Centres for Disease Control and Prevention did not immediately respond to Reuters' requests for comment.
The move from the US regulators comes less than a week after Europe's drug regulator said it was reviewing rare blood clots in four people in the United States who received the shot.
Australian Associated Press
